

USSN 10/034,981

- 2 -

Art Unit: 1615

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A method for the abortive treatment of acute migraine headache in ~~an~~ a subject comprising administering to the subject having a migraine headache an effective dose of intravenous valproate such that the abortive treatment of acute migraine headache is lessened or reduced in said subject occurs.
2. (Original) The method of claim 1, wherein administration is such that severity of acute migraine headache is lessened or reduced.
3. (Original) The method of claim 1, wherein administration is such that duration of acute migraine headache is lessened or reduced.
4. (Original) The method of claim 1, wherein administration is such that a symptom selected from the group consisting of nausea, photophobia, and phonophobia is lessened or reduced.
5. (Original) The method of claim 1, wherein about 100mg to 2000mg of valproate is administered to a subject.
6. (Original) The method of claim 1, wherein about 200mg to 1500mg of valproate is administered.
7. (Original) The method of claim 1, wherein about 300mg to 1000mg of valproate is administered.

USSN 10/034,981

- 3 -

Art Unit: 1615

8. (Original) The method of claim 1, wherein about 250mg to 750mg of valproate is administered.
9. (Original) The method of claim 1, wherein about 500mg valproate is administered to the subject.
10. (Original) The method of claim 1, wherein the valproate is administered to the subject over 30 minutes to 1 hour.
11. (Original) The method of claim 1, wherein the valproate is administered to the subject over 15 to 30 minutes.
12. (Original) The method of claim 1, wherein the valproate is administered to the subject over 5 to 15 minutes.
13. (Original) The method of claim 1, wherein the valproate is administered to the subject over 1 to 5 minutes.
14. (Original) The method of claim 1, wherein the valproate is administered to the subject in more than one dose.